Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Thoracic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Breast Neoplasms 35Neoplasm Metastasis 7Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Thyroid Neoplasms 4Thyroid Cancer, Papillary 3Sarcoma 3Pancreatic Neoplasms 3Neoplasms by Site 3Melanoma 3Lung Neoplasms 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Diseases 2Thoracic Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Ovarian Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Lung Diseases 2Esophageal Neoplasms 2Endometrial Neoplasms 2Endocrine System Diseases 2

Interventions

sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Carcinoma, Ovarian Epithelial × Breast × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡